Cancer basic research is the fundamental scientific investigation aimed at understanding the underlying biological mechanisms that drive cancer initiation, progression, and behavior at the molecular, cellular, and physiological levels. It focuses on discovering and elucidating core principles of cancer biology, encompassing diverse fields including cancer cell biology, genetics, epigenetics, metabolism, immunology, and the study of the tumor microenvironment (TME).
Organoid model-based basic research employs biologically relevant 3D organoid cultures as a primary tool for fundamental oncological discovery. Unlike conventional 2D cell lines, cancer organoids retain key characteristics of the native tissue, including stem cell hierarchies, cellular diversity, and architectural organization. This high physiological relevance enables researchers to dissect complex processes such as tumor initiation, progression, metastatic cascades, and therapy resistance in a controlled yet physiologically representative ex vivo setting.
A diverse array of well-established cancer organoid models serves as the cornerstone for robust and reproducible basic research, enabling investigators to explore disease-specific mechanisms in a physiologically relevant context. These models provide a critical bridge between simplistic monolayer cultures and complex animal models.
Patient-Derived Organoids (PDOs)
Generated directly from primary tumor tissue or biopsies, PDOs retain the mutational profile, cellular diversity, and drug response patterns of the individual patient's cancer, making them ideal for personalized medicine research and translational studies.
Genetically Engineered Organoids
Utilizing gene-editing technologies on normal tissue-derived or induced pluripotent stem cell (iPSC)-derived organoids to introduce specific oncogenic drivers or knockout tumor suppressors. This model is powerful for dissecting the sequential contribution of genetic alterations to tumorigenesis.
Incorporating non-cancerous cell types, such as cancer-associated fibroblasts (CAFs), immune cells (T-cells, NK cells), or vascular endothelial cells, into the organoid culture system. These models are essential for investigating the dynamic crosstalk within the TME, facilitating the study of tumor-stroma interactions and immune evasion mechanisms.
| Organoid Type | Description |
| Colorectal Cancer Organoids | Used to study Wnt signaling pathway dynamics, intestinal crypt homeostasis, mutation-specific phenotypes (e.g., APC, KRAS), and the role of the gut microbiome in tumorigenesis. |
| Breast Cancer Organoids | Employed to investigate hormone receptor signaling, epithelial-stromal interactions, heterogeneity across subtypes (ER+, HER2+, TNBC), and mechanisms of endocrine therapy resistance. |
| Pancreatic Cancer Organoids | Applied to model the dense desmoplastic stroma, analyze the impact of driver mutations (e.g., KRAS, TP53), and test strategies to overcome chemoresistance within a representative microenvironment. |
| Glioblastoma Organoids | Utilized to explore neural stem cell biology, tumor-neuron interactions, blood-brain barrier penetration studies, and the invasive behavior of glioma cells in a 3D context. |
Leveraging a robust technological platform, deep scientific expertise, and a commitment to rigor, Alfa Cytology delivers reliable and physiologically relevant data. Our comprehensive service supports every stage, from model establishment and validation to the design and execution of sophisticated experimental studies aimed at unraveling the molecular and cellular drivers of cancer. Through this integrated approach, we provide tailored research solutions, generating insights into cancer biology to effectively de-risk and inform downstream drug development and preclinical strategies.
Alfa Cytology's comprehensive model development services encompass an expansive library of malignancies, spanning various histological subtypes and stages. Our platform supports the development, validation, and application of these premier models, which recapitulate the key genetic, phenotypic, and functional hallmarks of their corresponding malignancies.
Utilizing diverse specimen and cell sources, our methodologies support multiple 3D culture formats such as scaffold-based, scaffold-free, and air-liquid interface (ALI) systems to meet specific experimental requirements.
Specialized 3D Matrices and Hydrogels
Utilizing a range of biologically relevant scaffolds, including basement membrane extracts (e.g., Matrigel) and tunable synthetic hydrogels, to provide the critical biochemical and biophysical cues necessary for proper cell polarization, architecture, and stem cell niche maintenance.
Employing microfluidic chip technology to create dynamic, multi-cellular tumor models. These systems introduce perfusion to mimic blood flow, physiological shear stress, and nutrient/oxygen gradients. They enable real-time analysis of processes like intravasation/extravasation and metastatic seeding within a controlled, miniaturized platform.
Leveraging 3D bioprinting technologies for the spatially precise deposition of cells and biomaterials. This allows for the engineering of complex, heterotypic tumor architectures, controlled spatial organization of stromal and immune cells, and the recreation of graded tumor-stroma interfaces to study invasive fronts and niche interactions systematically.
Driven by a deep commitment to scientific rigor and technical precision, our platform utilizes state-of-the-art characterization pipelines to deliver highly validated data. By combining optimized culturing protocols with advanced analytical suites, we empower researchers to bypass the constraints of conventional models and achieve breakthroughs in tumor biology.
Tumor Biology and Microenvironment Research Services
Designed to elucidate tumor-stroma crosstalk, angiogenesis, and metastatic processes. Services include co-culture systems with cancer-associated fibroblasts (CAFs), endothelial cells, or other stromal components, invasion/migration assays in 3D matrices, and analysis of extracellular matrix (ECM) remodeling.
Characterization of the complex interactions between malignant cells and the immune system is conducted through advanced co-culture assays. These services focus on T-cell infiltration, checkpoint inhibitor efficacy, and the modulation of the immunosuppressive landscape by myeloid-derived suppressor cells (MDSCs) or tumor-associated macrophages (TAMs). We provide services for establishing co-cultures of cancer organoids with autologous or engineered immune cells (T cells, NK cells, macrophages), enabling functional assays for immune cell cytotoxicity, exhaustion profiling, and evaluation of immunotherapeutic efficacy.
Molecular Biology Research Services
Elucidation of the molecular drivers of cancer is achieved through deep multi-omic profiling and functional assays. From investigating aberrant signaling pathways to analyzing epigenetic modifications and protein expression patterns, these services provide a holistic view of the cancer cell's internal machinery.
Alfa Cytology developed a novel 3D co-culture model utilizing patient-derived liver cancer organoids and matched cancer-associated fibroblasts (CAFs) to dissect stromal-mediated mechanisms of chemoresistance. The aim was to create a physiologically relevant system to evaluate the dynamic reciprocity between tumor cells and their microenvironment. Through an optimized Transwell system, the organoids and CAFs were integrated in a spatially relevant manner. Analysis revealed that the presence of CAFs significantly altered the organoids' morphological architecture and diameter. Furthermore, this model demonstrated that CAFs conferred a protective effect, substantially reducing the efficacy of standard chemotherapeutic agents on the cancer organoids compared to organoids cultured alone. This model successfully provided a robust platform for identifying specific signaling factors involved in resistance and for screening therapies aimed at disrupting these tumor-stroma interactions.
Fig.1 The effects of CAFs on organoids on a co-culture platform. (A) Schematic of the Transwell-based experimental setup for indirect co-culture. (B) Quantitative analysis of organoid diameters under monoculture versus CAF co-culture conditions. Data are presented as mean ± SEM (n=5; **p < 0.01).
Alfa Cytology's organoid model-based basic research services provide a powerful, physiologically relevant foundation for advancing your cancer research. By integrating cutting-edge 3D model technology with customized experimental design and expert execution, we empower researchers to uncover novel biological insights. To discuss how we can tailor our services to support your specific research objectives, please contact our scientific team for a detailed consultation.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.